359 related articles for article (PubMed ID: 31382410)
1. Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways.
Karvonen H; Barker H; Kaleva L; Niininen W; Ungureanu D
Cells; 2019 Aug; 8(8):. PubMed ID: 31382410
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.
Zhang S; Zhang H; Ghia EM; Huang J; Wu L; Zhang J; Lam S; Lei Y; He J; Cui B; Widhopf GF; Yu J; Schwab R; Messer K; Jiang W; Parker BA; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1370-1377. PubMed ID: 30622177
[TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.
Islam SS; Uddin M; Noman ASM; Akter H; Dity NJ; Basiruzzman M; Uddin F; Ahsan J; Annoor S; Alaiya AA; Al-Alwan M; Yeger H; Farhat WA
EBioMedicine; 2019 May; 43():211-224. PubMed ID: 31085100
[TBL] [Abstract][Full Text] [Related]
4. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
[TBL] [Abstract][Full Text] [Related]
5. The signaling protein Wnt5a promotes TGFβ1-mediated macrophage polarization and kidney fibrosis by inducing the transcriptional regulators Yap/Taz.
Feng Y; Liang Y; Zhu X; Wang M; Gui Y; Lu Q; Gu M; Xue X; Sun X; He W; Yang J; Johnson RL; Dai C
J Biol Chem; 2018 Dec; 293(50):19290-19302. PubMed ID: 30333225
[TBL] [Abstract][Full Text] [Related]
6. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer.
Li Z; Wang Y; Zhu Y; Yuan C; Wang D; Zhang W; Qi B; Qiu J; Song X; Ye J; Wu H; Jiang H; Liu L; Zhang Y; Song LN; Yang J; Cheng J
Mol Oncol; 2015 Jun; 9(6):1091-105. PubMed ID: 25704916
[TBL] [Abstract][Full Text] [Related]
7. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis.
Li C; Wang S; Xing Z; Lin A; Liang K; Song J; Hu Q; Yao J; Chen Z; Park PK; Hawke DH; Zhou J; Zhou Y; Zhang S; Liang H; Hung MC; Gallick GE; Han L; Lin C; Yang L
Nat Cell Biol; 2017 Feb; 19(2):106-119. PubMed ID: 28114269
[TBL] [Abstract][Full Text] [Related]
8. The signaling pathways activated by ROR1 in cancer.
Quezada MJ; Lopez-Bergami P
Cell Signal; 2023 Apr; 104():110588. PubMed ID: 36621728
[TBL] [Abstract][Full Text] [Related]
9. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
[TBL] [Abstract][Full Text] [Related]
10. The Hippo Signaling Pathway in Pancreatic Cancer.
Ansari D; Ohlsson H; Althini C; Bauden M; Zhou Q; Hu D; Andersson R
Anticancer Res; 2019 Jul; 39(7):3317-3321. PubMed ID: 31262852
[TBL] [Abstract][Full Text] [Related]
11. Wnt5a/ROR1 activates DAAM1 and promotes the migration in osteosarcoma cells.
Dai B; Shen Y; Yan T; Zhang A
Oncol Rep; 2020 Feb; 43(2):601-608. PubMed ID: 31894282
[TBL] [Abstract][Full Text] [Related]
12. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling.
Zheng L; Xiang C; Li X; Guo Q; Gao L; Ni H; Xia Y; Xi T
J Hematol Oncol; 2018 May; 11(1):72. PubMed ID: 29848346
[TBL] [Abstract][Full Text] [Related]
13. Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.
Yu J; Chen L; Chen Y; Hasan MK; Ghia EM; Zhang L; Wu R; Rassenti LZ; Widhopf GF; Shen Z; Briggs SP; Kipps TJ
Leukemia; 2017 Dec; 31(12):2608-2614. PubMed ID: 28465528
[TBL] [Abstract][Full Text] [Related]
14. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.
Hasan MK; Yu J; Widhopf GF; Rassenti LZ; Chen L; Shen Z; Briggs SP; Neuberg DS; Kipps TJ
Blood; 2018 Jul; 132(2):170-178. PubMed ID: 29678828
[TBL] [Abstract][Full Text] [Related]
15. [Regulation of differentiation of mesenchymal stem cells by the Hippo pathway effectors TAZ/YAP].
Men T; Piao SH; Teng CB
Yi Chuan; 2013 Nov; 35(11):1283-90. PubMed ID: 24579311
[TBL] [Abstract][Full Text] [Related]
16. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1.
Cao J; Wang X; Dai T; Wu Y; Zhang M; Cao R; Zhang R; Wang G; Jiang R; Zhou BP; Shi J; Kang T
Theranostics; 2018; 8(10):2739-2751. PubMed ID: 29774072
[No Abstract] [Full Text] [Related]
17. An emergent Wnt5a/YAP/TAZ regulatory circuit and its possible role in cancer.
Astudillo P
Semin Cell Dev Biol; 2022 May; 125():45-54. PubMed ID: 34764023
[TBL] [Abstract][Full Text] [Related]
18. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cell-derived CXCL16 promotes progression of gastric cancer cells by STAT3-mediated expression of Ror1.
Ikeda T; Nishita M; Hoshi K; Honda T; Kakeji Y; Minami Y
Cancer Sci; 2020 Apr; 111(4):1254-1265. PubMed ID: 32012403
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness.
Karvonen H; Arjama M; Kaleva L; Niininen W; Barker H; Koivisto-Korander R; Tapper J; Pakarinen P; Lassus H; Loukovaara M; Bützow R; Kallioniemi O; Murumägi A; Ungureanu D
Cell Death Dis; 2020 Sep; 11(9):790. PubMed ID: 32989221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
